News

NMD Pharma announced the dosing of the first patient in a Phase 2b clinical trial of NMD670, its investigational oral therapy for generalized myasthenia gravis (gMG). The SYNAPSE-MG trial (NCT06414954), recently cleared by the U.S. Food and Drug Administration (FDA), is assessing the treatment’s safety and…

A greater reduction in disease severity a month after surgery to remove the thymus gland in myasthenia gravis (MG) patients without a thymus tumor is linked with lower disease recurrence, a study in China suggests. Patients with a reduction of at least 36.7% in the Quantitative Myasthenia Gravis score…

Blood levels of interleukin-41 (IL-41) — a signaling molecule involved in immune responses — are found to be significantly elevated in people with myasthenia gravis (MG), and associated with disease severity and inflammatory markers, a study from China reports. These findings indicate “IL-41 may be essential to the [disease]…

Immunovant plans to prioritize development of its newer treatment candidate, IMVT-1402, over its Phase 3 candidate, batoclimab, for people with myasthenia gravis (MG), with tentative plans to launch a registrational clinical trial program of IMVT-1402 within the next year. Registrational studies are those that can back a…

Spreading awareness about myasthenia gravis (MG) during the month of June can be as simple as talking about the disease in your neighborhood and community. Hosting awareness events locally not only fosters engagement and relevance, but also helps people cope with the rarity of this autoimmune disease. MG is…

The case of a pregnant woman with myasthenia gravis (MG) who saw her disease worsen and who developed hydramnios — an abnormal buildup of fluid around the fetus during pregnancy — was described in a new report that researchers say highlights how variable the condition can be. Despite the…

Nearly six months of treatment with RemeGen’s telitacicept (RC18) lessened disease activity in adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor, according to data from a Phase 2 clinical trial in China. “Telitacicept demonstrated safety [and] good tolerability and reduced clinical…

Cartesian Therapeutics’ investigational cell therapy Descartes-08 has been granted regenerative medicine advanced therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA) for the treatment of myasthenia gravis (MG). RMAT status is intended for experimental regenerative medicines to treat, modify, reverse, or cure a serious or life-threatening…

Patients, especially women, experience a high degree of side effects from myasthenia gravis (MG) treatment, according to a U.K. survey examining real-world use of the medications. As steroid-sparing agents, mycophenolate mofetil (sold as CellCept) and methotrexate (sold as Trexall, among others) were less likely to be discontinued…

A woman with hard-to-treat generalized myasthenia gravis (gMG) who was seronegative, or tested negative for disease-driving self-directed antibodies, was successfully treated with off-label Vyvgart (efgartigimod alfa-fcab), as reported in a case study from Italy. According to researchers, this case provides evidence that limiting Vyvgart to MG patients with…